Immix Biopharma (IMMX) said Tuesday six patients dosed in a phase 1b safety run-in segment of a trial of its experimental NXC-201 treatment of relapsed or refractory AL Amyloidosis successfully completed the trial's safety evaluation.
The safety run-in segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells.
Immix said enrollment can now advance across US study sites at a dose of 450 million CAR-T cells.
AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow.
Price: 2.29, Change: -0.01, Percent Change: -0.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.